trial

Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia

NCTId NCT07268430
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 256 (actual)
Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Primary completion 2024-12-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
256 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2023-12-18
Primary completion
2024-12-25
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Lead Sponsor

Investigators

1
Gang Wang, M.D.Study Chair

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
256
Phase
NA
Primary Completion Date
2024-12-25
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gang Wang, M.D.
person